Systemic therapy of atopic dermatitis in children

Drugs

Volumn 69, Issue 3, 2009, Pages 297-306

  Ricci, Giampaolo ^a   Dondi, Arianna ^a   Patrizi, Annalisa ^a   Masi, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; BECLOMETASONE; CEPHALOSPORIN; CLINDAMYCIN; CYCLOSPORIN; EFALIZUMAB; FLUNISOLIDE; FUSIDIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PENICILLIN G; RECOMBINANT GAMMA INTERFERON;

ABDOMINAL DISCOMFORT; ATOPIC DERMATITIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; KIDNEY DISEASE; LIVER TOXICITY; LYMPHOCYTOPENIA; MICROCYTOSIS; MYCOSIS; NAUSEA; NEUTROPENIA; PARESTHESIA; PRURITUS; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VOMITING;

ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS;

EID: 62249192060     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969030-00005     Document Type: Review

References (72)

1. Asher MI, Montefort S, Björkstén B, et al., on behalf of the ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys [published erratum appears in Lancet 2007 Sep 29; 370 (9593): 1128]. Lancet 2006 Aug 26; 368 (9537): 733-43
2. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics 2008; 122: 812-24
3. Ricci G, Patrizi A, Baldi E, et al. Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol 2006 Nov; 55 (5): 765-71
4. Ricci G, Bendandi B, Bellini F, et al. Atopic dermatitis: quality of life of young Italian children and their families and correlation with severity score. Pediatr Allergy Immunol 2007 May; 18 (3): 245-9
5. Williams HC. Clinical practice: atopic dermatitis. N Engl J Med 2005 Jun 2; 352 (22): 2314-24
6. Ellis C, Luger T, Abeck D, et al., on behalf of the ICCAD II Faculty. International Consensus Conference on Atopic Dermatitis II (ICCAD II). Clinical update and current treatment strategies. Br J Dermatol 2003 May; 148 Suppl. 63: 3-10
7. Ricci G, Dondi A, Patrizi A. Role of topical calcineurin inhibitors on atopic dermatitis of children. Curr Med Chem 2007; 14 (14): 1579-91
8. Orlow SJ. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Pediatr Drugs 2007; 9 (5): 289-99
9. Williams HC, Grindlay DJC. What's new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007. Clin Exp Dermatol 2008; 33: 685-8
10. Olesen AB, Bang K, Juul S, et al. Stable incidence of atopic dermatitis among children in Denmark during the 1990s. Acta Derm Venereol 2005; 85 (3): 244-7
11. Broberg A, Svensson Å, Borres MP, et al. Atopic dermatitis in 5-6-year-old Swedish children: cumulative incidence, point prevalence, and severity scoring. Allergy 2000; 55: 1025-9
12. Dotterud K, Kvammen B, Lund E, et al. Prevalence and some clinical aspects of atopic dermatitis in the community of Sør-Varanger. Acta Dermatol Venereol (Stockh) 1995; 75: 50-3
13. Popescu CM, Popescu R, Williams H, et al. Community validation of the United Kingdom diagnostic criteria for atopic dermatitis in Romanian schoolchildren. Br J Dermatol 1998; 138: 436-42
14. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998; 139: 73-6
15. Boguniewicz M, Schmid-Grendelmeier P, Leung DYM. Atopic dermatitis. J Allergy Clin Immunol 2006 Jul; 118 (1): 40-3
16. Schmitt J, Schäkel K, Schmitt N, et al. Systemic treatment of severe atopic eczema: a systematic review. Acta Dermatol Venereol 2007; 87 (2): 100-11
17. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007 May; 21 (5): 606-19
18. Akdis CA, Akdis M, Bieber T, et al., on behalf of the European Academy of Allergology and Clinical Immunology/ American Academy of Allergy, Asthma and Immunology/ PRACTALL Consensus Group. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006 Aug; 61 (8): 969-87
19. European Task Force On Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31
20. Oranje AP, Glazenburg EJ, Wolkerstorfer A, et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007; 157: 645-8
21. Metz BJ. Highlights of the Society for Pediatric Dermatology Annual Meeting, July 12-15 2007, Chicago, Illinois. Conference report. Medscape Dermatology 2007 [online]. Available from URL: http://www.medscape.com/ viewarticle/ 562439 [Accessed 2007 Dec 18]
22. Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003 Dec; 49 (6): 1088-95
23. Heddle RJ, Soothill JF, Bulpitt CJ, et al. Combined oral and nasal beclomethasone dipropionate in children with atopic eczema: a randomized controlled trial. Br Med J (Clin Res Ed) 1984 Sep 15; 289 (6446): 651-4
24. La Rosa M, Musarra I, Ranno C, et al. A randomized, double-blind, placebo-controlled crossover trial for systemic flunisolide in the treatment of children with severe atopic dermatitis. Curr Therap Res 1995; 56: 720-6
25. Galli E, Chini L, Moschese V, et al. Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr 1994 Mar; 83 (3): 315-7
26. Levine LS, White PC. Disorders of Adrenal Glands. In: Behrman RE, Kliegman RM, Jenson HB, editors. Nelson Textbook of Pediatrics, 17th ed. Philadelphia (PA): Saunders, 2004: 1898-913
27. Deshmukh CT. Minimizing side effects of corticosteroids in children. Indian JDermatol Venereol Leprol 2007; 73: 218-21
28. Madan V, Griffiths CEM. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther 2007 Jul-Aug; 20 (4): 239-50
29. Griffiths CEM, Katsambas A, Dijkmans BAC, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 2006 Jul; 155 Suppl. 2: 1-16
30. Ho VCY, Griffiths CEM, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999 Aug; 141 (2): 283-91
31. Griffiths CEM, Durbertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004; 150 Suppl. 67: S11-23
32. Harper JI, Ahmed IA, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52-8
33. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol 1996 Jun; 34 (6): 1016-21
34. Bunikowski R, Staab D, Kussebi F, et al. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pediatr Allergy Immunol 2001; 12: 216-23
35. Ruperto N, Ravelli A, Castell E, et al., Pediatric Rheumatology Collaborative Study Group (PRCSG); Paediatric Rheumatology International Trials Organisation (PRINTO). Cyclosporine A in juvenile idiopathic arthritis: results of the PRCSG/PRINTO phase IV postmarketing surveillance study. Clin Exp Rheumatol 2006 Sep-Oct; 24 (5): 599-605
36. Ravelli A, Moretti C, Temporini F, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol 2002 Jul-Aug; 20 (4): 569-72
37. Meggit SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderateto-severe atopic eczema: a double-blind, randomized controlled trial. Lancet 2006; 367: 839-46
38. Lipozenèić J, Wolf R. Atopic dermatitis: an update and review of the literature. Dermatol Clin 2007 Oct; 25 (4): 605-12
39. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002 Aug; 147 (2): 324-30
40. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002 Aug; 147 (2): 308-15
41. Chang TT, Stevens SR. Atopic dermatitis: the role of recombinant interferon-gamma therapy. Am J Clin Dermatol 2002; 3: 175-83
42. Hanifin JM, Schneider LC, Leung DY, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993 Feb; 28 (2 Pt 1): 189-97
43. Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000 Jun; 42 (6): 1033-40
44. Wakim M, Alazard M, Yajima A, et al. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998 Aug; 81 (2): 153-8
45. Jolles S, Sewell C, Webster D, et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003; 83 (6): 433-7
46. Paul C, Lahfa M, Bachelez H, et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002; 147: 518-22
47. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). J Am Acad Dermatol 2007 Jan; 56 (1): e55-79
48. Berry M, Brightling C, Pavord I, et al. TNF-α in asthma. Curr Opin Pharmacol 2007 Jun; 7 (3): 279-82
49. Brightling C, Berry M, Amrani Y. Targeting TNF-α: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008 Jan; 121 (1): 5-10
50. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005 Mar; 52 (3 Pt 1): 522-6
51. Ricci G, Dondi A, Patrizi A. S. aureus overinfection in atopic dermatitis. J Pediatr Infect Dis 2008; 3: 83-90
52. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006 Apr; 144 (1): 1-9
53. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006 Jul; 118 (1): 3-21
54. Purcell K, Fergie J. The epidemic of methicillin-resistant Staphylococcus aureus colonization and infection in children: implications for community and hospital practice. J Pediatr Infect Dis 2006; 1 (1): 7-15
55. Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol 2008 Feb; 22 (2): 223-8
56. McHenry PM, Williams HC, Bingham EA. Management of atopic eczema. Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London. BMJ 1995 Apr 1; 310 (6983): 843-7
57. Riccioni G, Bucciarelli T, Mancini B, et al. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007; 14 (18): 1966-77
58. Möhrenschlager M, Darsow U, Schnopp C, et al. Atopic eczema: what's new? J Eur Acad Dermatol Venereol 2006 May; 20 (5): 503-11
59. Hsu C-J, Wang L-F. Emerging treatment of atopic dermatitis. Clinic Rev Allerg Immunol 2007; 33: 199-203
60. Grundmann-Kollmann K, Behrens L, Krähn K, et al. Successful treatment of severe refractory atopic dermatitis with mycophenolatemophetil. Br JDermatol 1999; 141: 175-6
61. Grundmann-Kollmann K, Podda M, Ochsendorf F, et al. Mycophenolate mophetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137: 870-3
62. Neuber K, Schwarz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mophetil. Br J Dermatol 2000; 143: 385-91
63. Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mophetil. Br J Dermatol 2001; 14: 638-9
64. Hansen ER, Buus S, Deleuran M, et al. Treatment of atopic dermatitis with mycophenolate mophetil. Br J Dermatol 2000; 143: 1324-6
65. Heller M, Shin HT, Orlow SJ, et al. Mycophenolate mophetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007; 157: 127-32
66. Chacko M, Weinberg JM. Efalizumab. Dermatol Ther 2007; 20: 265-9
67. Takiguchi R, Tofte S, Simpson B, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007 Feb; 56 (2): 222-7
68. Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T cell modulator efalizumab. Arch Dermatol 2006; 142: 555-8
69. Beck LA, Saini S. Wanted: a study with Omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 2006; 55: 540-1
70. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005 Aug; 53 (2): 338-40
71. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-72
72. Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55: 168-70